Tags

Type your tag names separated by a space and hit enter

Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
Eur J Neurol. 2008 Jul; 15(7):643-8.EJ

Abstract

Levodopa is the gold standard drug for the symptomatic control of Parkinson's disease (PD). However, long-term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re-emergence of symptoms because of wearing-off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half-life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open-label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose-fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa-modification strategies for the effective treatment of PD motor fluctuations in clinical practice.

Authors+Show Affiliations

INSERM, CIC04, Nantes, France and CHU Nantes, Clinique Neurologique, Nantes, France. philippe.damier@chu-nantes.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18582341

Citation

Damier, P, et al. "Levodopa/DDCI and Entacapone Is the Preferred Treatment for Parkinson's Disease Patients With Motor Fluctuations in Routine Practice: a Retrospective, Observational Analysis of a Large French Cohort." European Journal of Neurology, vol. 15, no. 7, 2008, pp. 643-8.
Damier P, Viallet F, Ziegler M, et al. Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. Eur J Neurol. 2008;15(7):643-8.
Damier, P., Viallet, F., Ziegler, M., Bourdeix, I., & Rerat, K. (2008). Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. European Journal of Neurology, 15(7), 643-8. https://doi.org/10.1111/j.1468-1331.2008.02165.x
Damier P, et al. Levodopa/DDCI and Entacapone Is the Preferred Treatment for Parkinson's Disease Patients With Motor Fluctuations in Routine Practice: a Retrospective, Observational Analysis of a Large French Cohort. Eur J Neurol. 2008;15(7):643-8. PubMed PMID: 18582341.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. AU - Damier,P, AU - Viallet,F, AU - Ziegler,M, AU - Bourdeix,I, AU - Rerat,K, PY - 2008/6/28/pubmed PY - 2008/8/13/medline PY - 2008/6/28/entrez SP - 643 EP - 8 JF - European journal of neurology JO - Eur J Neurol VL - 15 IS - 7 N2 - Levodopa is the gold standard drug for the symptomatic control of Parkinson's disease (PD). However, long-term treatment with conventional formulations [levodopa and a dopa decarboxylase inhibitor (DDCI)], is associated with re-emergence of symptoms because of wearing-off and dyskinesia. Treatment with levodopa/DDCI and entacapone extends the half-life of levodopa, avoiding deep troughs in levodopa plasma levels and providing more continuous delivery of levodopa to the brain. In this open-label, retrospective, observational study we investigated the effects of levodopa/DDCI and entacapone therapy in 800 PD patients with motor fluctuations. Levodopa/DDCI and entacapone treatment was assessed as good/very good in improving motor fluctuations (64%) and activities of daily living (ADL; 62%). The therapeutic utility was considered to be good/very good in 70% of cases. Moreover, there was a reduction in levodopa dose in 20% of patients. Neurologists preferred levodopa/DDCI and entacapone compared with increasing levodopa dosage, dose-fractionation or addition of a dopamine agonist (63%, 29% and 23% of patients respectively). Reasons included achieving more continuous dopaminergic stimulation (40%), reducing motor fluctuations (54%) and improving ADL (41%). This analysis reveals the preference of neurologists for levodopa/DDCI and entacapone over conventional levodopa-modification strategies for the effective treatment of PD motor fluctuations in clinical practice. SN - 1468-1331 UR - https://www.unboundmedicine.com/medline/citation/18582341/Levodopa/DDCI_and_entacapone_is_the_preferred_treatment_for_Parkinson's_disease_patients_with_motor_fluctuations_in_routine_practice:_a_retrospective_observational_analysis_of_a_large_French_cohort_ L2 - https://doi.org/10.1111/j.1468-1331.2008.02165.x DB - PRIME DP - Unbound Medicine ER -